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Abstract 
Maternal physiological hypercholesterolemia (MPH) allows a proper foetal 
development; however, maternal supraphysiological hypercholesterolemia (MSPH) associates 
with foetal endothelial dysfunction and early development of atherosclerosis. MSPH courses 
with reduced endothelium–dependent dilation of the human umbilical vein due to reduced 
endothelial nitric oxide synthase activity compared with MPH. Whether MSPH modifies the 
availability of the nitric oxide synthase cofactor tetrahydrobiopterin is unknown. We 
investigated whether MSPH–associated lower umbilical vein vascular reactivity results from 
reduced bioavailability of tetrahydrobiopterin. Total cholesterol <7.2 mmol/L was considered 
as maternal physiological hypercholesterolemia (n = 72 women) and ≥ 7.2 mmol/L as MSPH (n 
= 35 women). Umbilical veins rings were used for vascular reactivity assays (wire myography), 
and primary cultures of human umbilical vein endothelial cells (HUVECs) to measure nitric 
oxide synthase, GTP cyclohydrolase 1, and dihydrofolate reductase expression and activity, as 
well as tetrahydrobiopterin content. MSPH reduced the umbilical vein rings relaxation caused 
by calcitonine gene-related peptide, a phenomenon partially improved by incubation with 
sepiapterin. HUVECs from MSPH showed lower nitric oxide synthase activity (L-citrulline 
synthesis from L-arginine) without changes in its protein abundance, as well as reduced 
tetrahydrobiopterin level compared with MPH, a phenomenon reversed by incubation with 
sepiapterin. Expression and activity of GTP cyclohydrolase 1 was lower in MSPH, without 
changes in dihydrofolate reductase expression. MSPH is a pathophysiological condition 
reducing human umbilical vein reactivity due to lower bioavailability of tetrahydrobiopterin 
leading to lower NOS activity in the human umbilical vein endothelium. 
Keywords: tetrahydrobiopterin; fetal; endothelium; cholesterol; pregnancy 
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Abbreviations 
 
MPH  maternal physiological hypercholesterolemia 
MSPH  maternal supraphysiological hypercholesterolemia 
GTP  guanosine triphosphate 
GTPCH1 GTP cyclohydrolase 1 
DHFR  dihydrofolate reductase 
BH2  dihydrobiopterine 
BH4  tetrahydrobiopterine  
HUVECs human umbilical vein endothelial cells 
TCh  total cholesterol 
LDL  low density lipoprotein 
vLDL  very-low density lipoprotein 
HDL  high-density lipoprotein 
NO  nitric oxide 
eNOS  endothelial nitric oxide synthase 
CGRP  calcitonine gene related peptide 
L-NAME N
G
-nitro-L-arginine methyl ester  
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1. Introduction 
Human pregnancy courses with increased maternal content of total cholesterol (TCh), 
i.e., maternal physiological hypercholesterolemia in pregnancy (MPH), to satisfy the demand of 
lipids by the growing foetus [1].
 
However, some pregnant women show an excessive increase 
in TCh content over the MPH, i.e., maternal supraphysiological hypercholesterolemia in 
pregnancy (MSPH) [2-5]. MSPH associates with foetal endothelial dysfunction [4-6], early 
development of atherosclerosis [7,8], and cardiovascular disease [8-10]. MSPH associates with 
reduced synthesis of nitric oxide (NO) from human umbilical vein endothelial cells (HUVECs) 
and NO-dependent dilation of human umbilical vein rings compared with MPH [4], with a cut-
off point >7.3 mmol/L maternal TCh at term [4,5]. Additionally, HUVECs from MSPH show 
reduced endothelial NO synthase (eNOS) activity, without altering its protein abundance, 
compared with MPH [4-5]. In non-pregnant women, hypercholesterolemia leads to lower 
endothelium–derived NO by a mechanism involving reduced level of the NOS cofactor 
tetrahydrobiopterin (BH4) [11-18]. Thus, it is likely that BH4 is involved in the MSPH–
associated lower eNOS activity in the fetoplacental vasculature. 
BH4 is generated by the novo from guanosine triphosphate (GTP), where GTP 
cyclohydrolase 1 (GTPCH1) activity is the limiting step [19], and through a salvage pathway 
from sepiapterin [20],
 
where reduction of dihydrobiopterin (BH2) to BH4 is the limiting step 
requiring dihydrofolate reductase (DHFR) activity [19].
 
It is reported that high low-density 
lipoprotein (LDL) content associates with reduced NOS and GTPCH1 expression in rat 
vascular smooth muscle cells [21,22], suggesting that GTPCH1 may play a role in 
hypercholesterolemia. We hypothesize that BH4 level, and DHFR or GTPCH1 expression and 
activity will be altered in human fetoplacental endothelium from MSPH. The results show that 
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5 
reduced endothelium-dependent dilation of vein rings from MSPH is improved by incubation 
with sepiapterin. The cellular mechanisms involved in this phenomenon include reduced 
content of BH4 and GTPCH1 expression and activity without changes in DHFR expression in 
HUVECs from this pathological condition. 
 
2. Material and Methods 
 Full version of Material and Methods are available in the Supplementary Material.  
 
2.1 Study groups 
 Human placentas with their umbilical cords were collected from 107 full-term 
pregnancies (Table 1). The investigation conforms to the principles outlined in the Declaration 
of Helsinki. Ethics Committee approval from Faculty of Medicine of the Pontificia Universidad 
Católica de Chile and patient informed consents were obtained. Blood cholesterol level before 
pregnancy was obtained for women enrolled in the study. All pregnant women were screened 
for total blood cholesterol (TCh), high-density lipoprotein (HDL), low-density lipoprotein 
(LDL) or very-low density lipoprotein (vLDL) cholesterol and triglycerides in whole brachial 
venous blood taken during the first trimester, second trimester and at the term of pregnancy 
(third trimester). At birth, whole umbilical blood was collected and assayed for TCh, HDL-
cholesterol and triglycerides via enzymatic-colorimetric assays, from where LDL- and vLDL-
cholesterol were estimated [4,5].  
 
2.2 Blood cholesterol and triglyceride measurement  
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TCh, HDL-, LDL-, or vLDL-cholesterol and triglycerides (Tg) was determined in 
maternal whole brachial venous blood taken at term of pregnancy as described [4,5]. Women 
with <7.2 mmol/L TCh were considered as MPH and with ≥7.2 mmol/L TCh corresponded to 
MSPH in this study, based in the cut-off point for MSPH, a value from when human 
fetoplacental endothelial and vascular dysfunction is seen, as previously reported [4,5]. 
 
2.3 Human umbilical vein reactivity 
 Isometric force was measured in a myograph in umbilical vein rings in response to 
calcitonine gene related peptide (CGRP, 0.1 – 1000 nmol/L, 5 minutes) in 32.5 mmol/L KCl 
preconstricted vessels, in the absence or presence of 100 µmol/L N
G
-nitro-L-arginine methyl 
ester (L-NAME, NOS inhibitor, 30 minutes), 100 µmol/L sepiapterin (1 hour) or 5 mmol/L 2,4-
diamino-6-hydroxypyrimidine (DAHP, 1 hour, GTPCH1 inhibitor) (Sigma-Aldrich, St Louis, 
MO, USA), as reported [4,5,23]. 
 
2.4 Cell culture  
 HUVECs were isolated by collagenase digestion from umbilical cords at birth from 
pregnancies with MPH or MSPH and cultured as described [4,5]. Experiments were performed 
in the absence or presence of L-NAME (100 µmol/L, 30 minutes), sepiapterin (100 µmol/L, 24 
hours) and/or DAHP (5 mmol/L, 12 hours) [24,25].  
 
2.5 Reverse transcription and quantitative RT-PCR 
 Total RNA was isolated using the Qiagen RNAeasy kit (Qiagen, Crawley, UK). RNA 
quality and integrity were insured by gel visualization and spectrophotometric analysis 
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7 
(OD260/280), quantified at 260 nm. Aliquots (1 g) of total RNA were reversed transcribed into 
cDNA as described [26]. Quantitative RT-PCR was performed using a Step One real time PCR 
system (Applied Biosystem, CA, USA) as described [26]. Oligonucleotide primers for GCH1, 
DHFR and 28S were used. 
 
2.6 Western blotting 
 Total protein was probed with primary polyclonal rabbit anti-total eNOS (1:200 
dilution, 2 hours, room temperature) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
monoclonal mouse anti-eNOS phosphorylated at Serine
1177
 (PSer1177-eNOS, 1:1000 dilution, 
1 hour, room temperature) or anti-eNOS phosphorylated at Threonine
495
 (PThr495-eNOS, 
1:1000 dilution, 1 hour, room temperature) (BD Transduction Laboratories, San Jose, CA, 
USA), monoclonal rat anti-GTPCH1 (1:1000 dilution, 8 hours, 4°C) and mouse anti-ß-actin 
(1:5000, 1 hour, room temperature) (Sigma-Aldrich) antibodies [4].  
 
2.7 eNOS monomer/dimer determination 
eNOS dimers and monomers were determined following a modification of a previously 
described method [27]. Confluent HUVECs from MPH and MSPH pregnancies were incubated 
with sepiapterin (100 µmol/L, 24 hours) or L-NAME (100 µmol/L, 30 minutes) and harvested 
in lysis buffer (20 mmol/L Tris/HCl (pH 7.4), 150 mmol/L NaCl, 2 mmol/L EGTA, 2 mmol/L 
EDTA, 0.5% Nonidet P-40, 1% Triton X100). Total protein were mixed with Laemmli buffer 
(0.32 mol/L Tris/HCl (pH 6.8), 0.5 mol/L glycine, 10% sodium dodecylsulphate, 50% glycerol, 
0.03% bromophenol blue) and separated in a 6% reducing polyacrylamide gel (2.5% 2-
mercaptoethanol). Proteins were probed for total eNOS and ß-actin as above.  
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2.8 NOS activity  
 NOS activity was assayed by determination of intracellular content of L-citrulline was 
determined by high performance liquid chromatography (HPLC) in confluent HUVECs in the 
absence or presence of 100 µmol/L N
G
-nitro-L-arginine methyl ester (L-NAME, inhibitor of 
NOS activity), as reported [26]. 
 
2.9 Intracellular reactive oxygen species (ROS) determination 
 Intracellular ROS levels were determined using the fluorescent dye 5-(and-6)-
chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Molecular Probes, 
Leiden, The Netherlands) as previously described [28]. Cells were exposed (30 minutes, 37°C) 
to 10 μmol/L of CM-H2DCFDA and fluorescence (λexc/λem: 495/520 nm) was determined in an 
Infinite M200 Pro (Tecan, Untersbergstr, Austria) microplate reader. 
 
2.10 Tetrahydrobiopterin (BH4) determination 
 The level of BH4 was determined by an acid-base oxidation method followed by 
fluorometric detection by HPLC as described [28]. 
 
2.11 GTPCH1 activity 
 GTPCH1 activity was determined as iodine oxidation of neopterin synthesized from 
GTP by HPLC activity following a modification of the method described by Werner-Felmayer 
& Gross [29]. Basal activity of the enzyme was quantified in the absence of exogenous GTP, 
and enzyme activity was induced by addition of 10 µL of 10 mmol/L GTP. 
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2.12 Statistical analysis  
 Values for lipids are given as mean ± S.D. For assays in vitro the values are mean ± 
S.E.M., where n indicates the number of different cell cultures (3-4 replicates). Comparison 
between groups was performed by parametric or non-parametric tests (see Supplemental 
Material and Methods). P<0.05 was considered statistically significant. 
 
3. Results 
3.1 Study groups 
All pregnant women coursed with a normal pregnancy and showed comparable age, 
height, weight, basal glycaemia and OGTT (Table 1). Maternal weight and body mass index 
increased as pregnancy progressed in MPH and MSPH. Systolic and diastolic blood pressure at 
3
rd
 trimester were higher than at 1
st
 trimester in both groups of pregnant women. None of the 
maternal or newborn variables were significantly altered when compared between MPH and 
MSPH.  
 
3.2 Maternal plasma lipids 
 The maternal blood levels for TCh and LDL in the MSPH group were higher to in the 
MPH group at term of pregnancy (Table 2). However, HDL, vLDL and Tg levels were similar 
between both groups. 
 
3.3 Umbilical vein reactivity 
 In the absence of L-NAME, CGRP caused a maximal dilation (Dmax) of umbilical vein 
rings from MPH (Dmax = 24  3%) (Figure 1A) that was higher than in vessels from MSPH 
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(Dmax = 1.5  0.5%) (Figure 1B). The CGRP Dmax in MPH was unaltered by sepiapterin; 
however, this molecule increased CGRP Dmax (10  1%) in vein rings from MSPH. DAHP 
caused a reduction in the CGRP Dmax (15  1%) in MPH, but did not alter this value in vein 
rings from MSPH. CGRP EC50 value was higher in MSPH compared with MPH, an effect 
reversed by sepiapterin and partially reduced by DAHP (Table 3).  
 L-NAME blocked CGRP–dilation in vein rings from MPH and MSPH, and this effect 
was unaltered by sepiapterin or DAHP. All the CGRP EC50 values in the presence of L-NAME 
were higher than in the absence of this inhibitor in MPH (Table 3). The CGRP EC50 in the 
presence DAHP was unaltered, but it was reduced in the presence of sepiapterin in MPH (Table 
3). SNP caused a comparable dilation in veins from MPH and MSPH in the absence or 
presence of sepiapterin or DAHP (Figure 1C). 
 
3.4 eNOS expression and NOS activity 
 L-Citrulline content in HUVECs from MSPH was lower than in cells from MPH, and 
was reduced by L-NAME to similar values in cells from both conditions (Figure 2A). 
Sepiapterin did not alter L-citrulline content in MPH, but caused an increase in MSPH reaching 
values that were higher (3.1  0.4 fold) than those in MPH. L-NAME reduced L-citrulline 
content in the presence of sepiapterin. L-NAME–inhibited L-citrulline content (i.e., NOS 
activity) was lower in MSPH compared with MPH (Figure 2B). Incubation of cells with 
sepiapterin caused an increase in NOS activity in MSPH, but not in MPH.  
 Total eNOS protein abundance was unaltered in MSPH in the absence or presence of L-
NAME or sepiapterin (Figure 3A). However, PThr495-eNOS (Figure 3B) and PSer1177-eNOS 
(Figure 3C) were lower in MSPH, and unaltered by L-NAME or sepiapterin.  
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3.5  Intracellular ROS  
 Intracellular level of ROS was higher in HUVECs from MSPH compared with MPH 
(Figure 4A). Incubation of cells with sepiapterin did not alter ROS level in cells from MSPH or 
MPH, a phenomenon that was similar in the absence or presence of L-NAME (Figure 4B).  
 
3.6 eNOS monomer and dimer 
 Cells from MSPH show similar levels of monomeric (Figure 5A,B) and dimeric (Figure 
5A,C) eNOS. Incubation of cells with sepiapterin caused a significant reduction in eNOS 
monomer, but an increase in eNOS dimer proteins, leading to a lower eNOS monomer/dimer 
ratio (Figure 5D). Incubation of cells with L-NAME caused a minor pronounced effect on 
eNOS monomer/dimer ratio.   
 
3.7 BH4 content  
 Total biopterins (i.e., BH4 + BH2 + biopterins) and BH4 content were lower in MSPH 
compared with MPH in the absence of sepiapterin (Figure 6A). Out of total biopterins, the BH4 
content in cells from MSPH was lower than in cells from MPH. Incubation of cells with 
sepiapterin caused an increase in total biopterins and BH4 content reaching similar values in 
cells from both conditions. The absolute increase in total biopterins and BH4 contents caused 
by sepiapterin were similar for MPH or MSPH; however, this molecule caused a higher fold of 
increase in cells from MSPH (3.1  0.5 fold) compared with MPH (1.8  0.4 fold).  
 
3.8 DHFR and GTPCH1 expression and activity  
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The DHFR mRNA expression was unaltered in cells from MSPH compared with MPH 
(Figure 6B); however, GCH1 mRNA expression (Figure 6C) and GTPCH1 protein abundance 
(Figure 6D) were lower in cells from MSPH. Generation of neopterin was also lower in MSPH 
compared with MPH (Figure 6E). Neopterin content was increased by GTP in cells from MPH, 
an effect blocked by DAHP. However, GTP did not alter neopterin content in the absence or 
presence of DAHP in cells from MSPH. DAHP reduced neopterin content in cells from MPH, 
but not from MSPH.  
 
4. Discussion 
 This study shows that MSPH–associated reduction in the dilation of the human 
umbilical vein rings [4,5] is partially recovered by sepiapterin, a substrate for BH4 biosynthesis, 
via a mechanism involving increased NOS activity. Additionally, MSPH associates with 
reduced expression and activity of GTPCH1 in HUVECs. Thus, an increase in the maternal 
plasma level of TCh in MSPH results in reduced GCH1 expression and GTPCH1 protein 
abundance and activity in the human fetoplacental vasculature. This study also confirms the 
previously proposed cut-off point for MSPH–associated reduction in the dilation of human 
umbilical vein rings (>7.2 – 7.5 mmol/L TCh at term) [4,5] and extended this observation to 
show reduced BH4 content in HUVECs from MSPH in women with TCh over this cut-off point. 
 MSPH associates with reduced umbilical vein dilation in response to the endothelium–
dependent vasodilator CGRP [30] with EC50 values that were 18 fold higher in MSPH 
compared with vein rings from MPH, confirming previous observations in this umbilical vessel 
[4,5]. Since dilation caused by sodium nitroprusside (SNP), a spontaneous NO donor, was 
similar in MSPH and MPH, the umbilical vein endothelium rather than the vascular smooth 
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muscle is likely altered in MSPH. A major findings in this study is that reduced dilation of vein 
rings in response to CGRP in MSPH was reversed by sepiapterin suggesting that a reduced BH4 
content in human umbilical vein endothelium could limit CGRP–mediated dilation in these 
vessels. This phenomenon seems to occur only in vein rings from MSPH since sepiapterin 
increased the sensitivity to CGRP in these vessels (EC50
 
in the absence vs presence of 
sepiapterin (MSPH-EC50
–Sep/+Sep
) 920), but not in vein rings from MPH (MPH-EC50
–Sep/+Sep
 
1). Thus, this data strongly suggest that a BH4 deficiency could result in lower umbilical vein 
endothelium–dependent reactivity in pregnancies where the mother courses with MSPH. 
 Reversal of the MSPH–associated lower umbilical vein dilation by sepiapterin could 
result from modulation of NOS activity or by an antioxidant effect of BH4. The latter is 
supported by findings showing that BH4 acts as scavenger for reactive oxygen species (ROS) 
increasing NO bioavailability [31,32]. Interestingly, ROS formation was higher in MSPH, an 
effect unaltered by sepiapterin. Since sepiapterin caused only a partial restoration of the 
MSPH–reduced umbilical vein dilation it is suggested that reduced dilation may results from a 
dual effect including lower BH4 bioavailability for NOS activity and increased ROS generation 
in this vascular tissue. Furthermore, sepiapterin–dependent restoration of the dilation of vein 
rings in response to CGRP associates with higher eNOS activity in HUVECs from MSPH. 
Accordingly, MSPH–reduced BH4 content in HUVECs was restored by sepiapterin to levels 
detected in cells from MPH. Additional assays show that incubation of cells with sepiapterin 
did not alter the MSPH–associated lower level of activatory (Serine1177) or inhibitory (Thr495) 
phosphorylation states of eNOS, or the total protein abundance of this enzyme. Thus, the BH4 
bioavailability rather than eNOS protein abundance or phosphorylation states at these specific 
residues are likely accounting for the umbilical vein reactivity restoration by sepiapterin. 
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Additionally, sepiapterin increased the formation of eNOS dimers (i.e., coupled eNOS) [11], an 
effect that was similar in cells from MPH or MSPH. Thus, sepiapterin restores the human 
umbilical vein endothelial dysfunction detected in MSPH, a phenomenon that involves higher 
eNOS activity, likely not be due to increased eNOS coupling in MSPH, agreeing with reports 
in coronary arterioles from patients with atherosclerosis [33]. Interestingly, MSPH associates 
with reduced content of total biopterins in HUVECs, which could result from a lower BH4 
content (reduction in total biopterins content / reduction in BH4 content 1.2). Thus, a lower de 
novo synthesis of biopterins (from GTP to BH4) in MSPH is likely. These results differ from 
those reported in diabetes mellitus, where the level of BH4 was reduced without changes in the 
total level of biopterins, which results from BH4 loss by oxidative conversion of BH4 to BH2 
rather than a change in biosynthesis of biopterins [31,32]. Since MSPH associates with reduced 
activity of GTPCH1, and because this reduction (83%) was higher than the reduction seen for 
its protein abundance (57%), a lower GTPCH1–dependent de novo synthesis of biopterins in 
HUVECs from MSPH is feasible. This is supported by findings showing that atherosclerosis–
associated reduction in endothelial BH4 level result from inhibition of GTPCH1 activity or 
from oxidative degradation of BH4 by peroxynitrite rather than by regulation of the GTPCH1 
expression [34].  
 Although the synthesis of total biopterins and BH4 is reduced in MSPH, BH4 reduction 
in relation to total biopterins was lower in MSPH (MSPH
BH4/total biopterins
 52%) compared with 
MPH (MPH
BH4/total biopterins
 85%). Thus, a larger increase in BH2 compared with BH4 content in 
MSPH is likely.  It is reported that dihydrofolate reductase (DHFR) regenerates BH4 from BH2 
and that BH4/BH2 ratio is reduced when the total biopterins availability is reduced [35]. Our 
results show that DHFR expression was unaltered in MSPH, suggesting that BH4 generation 
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from BH2 is likely to be normal in MSPH. Alternatively, a reduced BH4/total biopterins ratio in 
MSPH could results from higher oxidation of BH4 to form BH2 as reported in hyperglycaemia 
where a reduced BH4 level instead of increased BH2 level is seen under oxidative stress 
[28,31]. Since pregnant women coursing with TCh >7.2 mmol/L show increased oxidative 
stress in the maternal and fetal blood, and in homogenized placenta [36,37],
 
an oxidative state 
in MSPH could also contribute to the altered proportion of BH4 in relation to total biopterins.  
In summary MSPH is a maternal condition that leads to endothelial dysfunction of the 
fetoplacental vasculature by a mechanism involving reduced synthesis of BH4. We have 
identified a new mechanism involved in the fetoplacental vascular alterations described for 
MSPH. Because this study has been performed in primary cultures of HUVECs and vein rings 
in vitro, the possibility that these alterations reflect alterations in the foetal vasculature should 
be considered with caution. However, we propose the possibility of BH4 as a new therapeutic 
target to prevent the initiation and/or progression of MSPH–associated foetal cardiovascular 
disease. This is supported by findings showing that restoration of BH4 content restores the 
endothelial dysfunction seen in pathological conditions coursing with a reduced level of this 
molecule including patients coursing with hypercholesterolemia [12,14,15,38,39]. Therefore, 
the findings described in this study could be considered in therapeutic protocols for prevention 
of fetoplacental vascular dysfunction in human pregnancies with MSPH aiming to reduce the 
potential consequences in the health of the newborn and in its adulthood. 
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Figure 1. Human umbilical vein rings reactivity in MPH and MSPH.  Dilation in response 
to calcitonine gene-related peptide (CGRP, 5 minutes) in human umbilical vein rings at 
birth from pregnancies where the mother showed (A) maternal physiological 
hypercholesterolemia (MPH, total plasma cholesterol 6.4 mmol/L (range 4.0-7.2 
mmol/L)) or (B) maternal supraphysiological hypercholesterolemia (MSPH, total plasma 
cholesterol 8.4 mmol/L (range 7.6-10.8 mmol/L)). The relative responses were expressed 
as percentage of the fraction of the initial vessel response to KCl (see Methods). Vein 
rings were preincubated in the absence (Control, white symbols) or in the presence  (grey 
symbols) of 100 μmol/L NG- nitro-L-arginine methylester (L-NAME, 30 minutes), 100 
μmol/L sepiapterin (1 hour), 5 mmol/L 2,4-diamino-6-hydroxypyrimidine (DAHP, 1 
hour). C. Dilation in response to 10 μmol/L sodium nitroprusside (5 minutes) in umbilical 
vein rings from MPH or MSPH. In A, *P<0.05 vs Control in the absence of L-NAME. 
All values in the presence of L-NAME (except -11 log mol/L CGRP) are significantly 
different (P<0.05) from values in the absence of L-NAME. In B, Values in the presence 
of sepiapterin in absence of L-NAME (except -11 log mol/L CGRP) are significantly 
different (P<0.05) from all other values. Values are mean ± S.E.M. (n = 12–18). 
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Figure 2.  Tetrahydrobiopterin involvement on nitric oxide synthase activity. A. L-
Citrulline content in primary cultures of human umbilical vein endothelial cells 
(HUVECs) from pregnancies where the mother showed maternal physiological 
hypercholesterolemia (MPH) or maternal supraphysiological hypercholesterolemia 
(MSPH) in the absence (–) or presence (+) of 100 μmol/L NG-nitro-L-arginine 
methylester (L-NAME, 30 minutes) and/or 100 μmol/L sepiapterin (24 hours) (see 
Methods). B. NOS activity estimated as the fraction of L-citrulline formation inhibited by 
L-NAME in the absence (–) or presence (+) of sepiapterin as in A. In A, *P<0.05 vs 
corresponding values in MPH, †P<0.05 vs all other corresponding values in MPH or 
MPSH, ‡P<0.05 vs value in the absence of L-NAME and sepiapterin in MSPH. In B, 
*P<0.05 vs corresponding values in MPH, †P<0.05 vs corresponding value in MPSH in 
the absence of sepiapterin. Values are mean ± S.E.M. (n = 6). 
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 Figure 3.  Tetrahydrobiopterin involvement on nitric oxide synthase expression. A. 
Western blots (representative blot of other 8 different umbilical veins from different 
patients) for total endothelial nitric oxide synthase (Total eNOS), or phosphorylated 
eNOS at Serine
1177
 (P~Ser
1177
-eNOS) or Threonine
495
 (P~Thr
495
-eNOS) in primary 
cultures of human umbilical vein endothelial cells (HUVECs) (β-actin was internal 
control) from pregnancies where the mother showed maternal physiological 
hypercholesterolemia (MPH) or maternal supraphysiological hypercholesterolemia 
(MSPH). Experiments were performed in cells incubated in the absence (–) or presence 
(+)   of 100 μmol/L NG-nitro-L-arginine methylester (L-NAME, 30 minutes) or 100 
μmol/L sepiapterin (24 hours) (see Methods). Lower panel: Total eNOS/β-actin ratio 
densitometries normalized to 1 in MPH in the absence of L-NAME and sepiapterin. B. 
P~Ser
1177
-eNOS/total eNOS ratio densitometries normalized to 1 in MPH as in A. C. 
P~Thr
495
-eNOS/total eNOS ratio densitometries normalized to 1 in MPH as in A. 
*P<0.05 vs corresponding values in MPH. Values are mean ± S.E.M. (n = 6). 
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Figure 4. MSPH–modulation of ROS generation. A. Reactive oxygen species (ROS) in 
primary cultures of human umbilical vein endothelial cells (HUVECs) from pregnancies 
where the mother showed maternal physiological hypercholesterolemia (MPH) or 
maternal supraphysiological hypercholesterolemia (MSPH). Relative fluorescence units 
(RFU) was measured in cells preloaded with 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate in the absence (–) and/or presence (+) of 100 
μmol/L NG-nitro-L-arginine methylester (L-NAME, 30 minutes) or 100 μmol/L 
sepiapterin (24 hours) (see Methods). B. ROS generation expressed as the fraction of 
RFU inhibited by L-NAME in the absence (–) or presence (+) of sepiapterin as in A. 
*P<0.05 vs corresponding values in MPH. Values are mean ± S.E.M. (n = 5). 
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Figure 5. Endothelial nitric oxide synthase monomer/dimer formation in MSPH.  A. 
Western blots (representative blot of other 6 different umbilical veins from different 
patients) for endothelial nitric oxide synthase (eNOS) monomers and dimers in primary 
cultures of human umbilical vein endothelial cells (HUVECs) (β-actin was internal 
control) from pregnancies where the mother showed maternal physiological 
hypercholesterolemia (MPH) or maternal supraphysiological hypercholesterolemia 
(MSPH). Experiments were performed in cells incubated in the absence (–) or presence 
(+)   of 100 μmol/L NG-nitro-L-arginine methylester (L-NAME, 30 minutes) or 100 
μmol/L sepiapterin (24 hours) (see Methods). B. eNOS monomers/β-actin ratio 
densitometries normalized to 1 in MPH in the absence of L-NAME and sepiapterin. C. 
eNOS dimers/β-actin ratio densitometries normalized to 1 in MPH as in B. C. eNOS 
monomer/dimer ratio densitometries normalized to 1 in MPH as in B. *P<0.05 vs all 
other corresponding values. †P<0.05 vs values in the presence of L-NAME. Values are 
mean ± S.E.M. (n = 6). 
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Figure 6. Biopterin availability in HUVECs from MPH and MSPH. A. Total biopterins 
concentration (Total) and tetrahydrobiopterin (BH4) in primary cultures of human 
umbilical vein endothelial cells (HUVECs) from pregnancies where the mother exhibited 
maternal physiological hypercholesterolemia (MPH) or maternal supraphysiological 
hypercholesterolemia (MSPH) in the absence (–Sepiapterin) or in the presence 
(+Sepiapterin) of 100 μmol/L sepiapterin (24 hours) (see Methods). B. Dihydrofolate 
reductase (DHFR) and GTP cyclohydrolase 1 (GCH1) mRNA expression relative to 28S 
rRNA (internal reference) in HUVECs from MPH and MSPH. C. Western blots 
(representative blot of other 6 different umbilical veins from different patients) for 
GTPCH1 in HUVECs (β-actin was internal control) from MPH and MSPH pregnancies. 
Lower panel: GTPCH1/β-actin ratio densitometries normalized to 1 in MPH. D. 
Neopterin formation in HUVECs from MPH or MSPH in the absence (–) or presence (+) 
of 0.7 mmol/L GTP (2 hours) or 5 mmol/L 2,4-diamino-6-hydroxypyrimidine (DAHP, 1 
hour). In A, *P<0.04 vs corresponding values in MPH, †P<0.01 vs corresponding values 
in (–Sepiapterin. In B and C, *P<0.03 vs MPH. In D, *P<0.02 for corresponding values 
in MPH, †P<0.04 vs all other values in MPH. Values are mean ± S.E.M. (n = 6–10).
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Table 1. Clinical variables of pregnant women and newborns 
 
Variables MPH (n = 72) MSPH (n = 35) 
 
Maternal    
    
Age (years) 29.2 ± 5 (18-43)  29.7 ± 6 (17-40) 
Height (m) 1.61 ± 0.05 (1.50-1.80)  1.61 ± 0.06 (1.47-1.75) 
Weight (kg)    
       First trimester 61.6 ± 8 (43-83)  59.8 ± 9.8 (46-90) 
       Second trimester 65.9 ± 7 * (51-87)  63.7 ± 8 * (46-78) 
       Third trimester 72.4 ± 7 † (55-92)  71.1 ± 7 † (50-80) 
BMI (kg/m
2
)    
       First trimester 23.7 ± 4 (17-25)  22.5 ± 3 (19-25) 
       Second trimester 25.2
 
 ± 3 * (20-28)  24.6 ± 3
 
* (19-27) 
       Third trimester 27.8 ± 3 † (22-31)  27.5 ± 3
 † (21-31) 
Systolic blood pressure (mmHg)    
       First trimester 107.3 ± 9 (90-130)  104.6 ± 11 (90-122) 
       Second trimester 107.6 ± 11 (90-140)  106.6 ± 11 (90-120) 
       Third trimester 110.1 ± 9 * (92-135)  112.7
 
± 13 * (90-140) 
Diastolic blood pressure (mmHg)    
       First trimester 64.5 ± 10(50-84)  65.6 ± 8 (58-80) 
       Second trimester 66.2 ± 8 (50-86)  65.7 ± 8 (50-80) 
       Third trimester 69.7 ± 10 * (50-120)  70.1 ± 9 * (60-88) 
OGTT (mmol/L)    
       Glycemia basal 4.2 ± 0.6 (3.6-5.1)  4.1 ± 0.6 (3.7-4.7) 
       Glycemia 2 hours after glucose 5.9 ± 1 (4.8-7.8)  5.8 ± 1 (4.2-7.8) 
    
Newborn    
    
Birth Weight (gr) 3371 ± 380 (2640-4170)  3354 ± 386 (2610-4020) 
Heigth (cm) 50.3 ± 2 (46-54)  49.8 ± 2 (46-54) 
Gestational age (week)  38.9 ± 1 (37-41)  39 ± 1 (37-41) 
Sex (female/male) 35/37  18/17 
 
Women with maternal physiological (MPH, <7.2 mmol/L total cholesterol) or 
supraphysiological hypercholesterolemia (MSPH, ≥7.2 mmol/L total cholesterol) at term of 
pregnancy were included (see Methods). Weight, body mass index (BMI) and blood pressure 
were determined in the three trimesters of pregnancy. OGTT, oral glucose tolerance test. 
*P<0.05 versus corresponding values at first trimester of pregnancy, †P<0.05 versus values at 
first and second trimesters of pregnancy. Data are mean ± S.D. (range).  
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Table 2. Lipids values in the maternal blood at term of pregnancy  
 
 
 
MPH (n = 72) 
 
 
MSPH (n = 35) 
 
 
TCh  6.2 ± 0.8 (3.7-7.2)  8.3± 0.9 * (7.3-10.8) 
HDL  1.9 ± 0.4 (1-2.9)  1.9 ± 0.5 (0.7-3.8) 
LDL  3.1 ± 0.7 (1.3-4.8)  5 ± 0.9 * (3.1-7.2) 
vLDL  1.2 ± 0.3 (0.8-2.4)  1.3  ± 0.2 (0.7-1.9) 
Triglycerides  2.7 ± 0.7 (1.8-4.6)  2.8 ± 0.6 (1.6-4.2) 
 
Maternal blood level (mmol/L) of total cholesterol (TCh), high (HDL), low (LDL) or very low 
(vLDL) density lipoprotein-cholesterol and triglycerides was determined at term of pregnancy 
in women exhibiting maternal physiological (MPH, <7.2 mmol/L TCh) or supraphysiological 
(MSPH, ≥7.2 mmol/L TCh) hypercholesterolemia in pregnancy (see Methods). *P<0.05 versus 
corresponding values in MPH. Values are mean ± S.D. (range).  
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Umbilical vein rings were obtained from term pregnancies where women exhibited maternal 
physiological (MPH, <7.2 mmol/L TCh) or supraphysiological (MSPH, ≥7.2 mmol/L TCh) 
hypercholesterolemia in pregnancy (see Methods). Vein rings were incubated in the absence 
(Without) or presence (With) of 100 mol/L NG-nitro-L-arginine methyl ester (L-NAME, 30 
minutes), 100 mol/L sepiapterin (1 hour) or 5 mmol/L 2,4-diamino-6-hydroxypyrimidine 
(DAHP, 1 hour) and the response to calcitonine gene related peptide (CGRP, 0.1 – 1000 
nmol/L, 5 minutes) (CGRP) was assayed. CGRP half-maximal effective concentration (EC50) 
was calculated (see Methods). *P<0.05 versus corresponding value in MPH, †P<0.05 versus 
corresponding values in Without L-NAME, Values are mean  S.E.M. (n = 4 – 12). n.m., not 
measurable. 
Table 3. CGRP dilation in human umbilical vein rings 
   
EC50 (nmol/L) 
 
   MPH  MSPH  
      
Without L-NAME      
 Control  1.02  0.02  18.4  3.3 *  
 Sepiapterin  1.04  0.02  0.02  0.001 *  
 DAHP  1.60  0.02  9.01  0.5 *  
With L-NAME      
 Control    8.4  0.84 †  n.m.  
 Sepiapterin    5.6  1 †  n.m.  
 DAHP  11.8  0.17 †  n.m.  
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Figure 1 
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Highlights 
 
1.  MSPH associates with reduced umbilical vein dilation.  
2. HUVECs from MSPH show reduced BH4 synthesis. 
3. The substrate for BH4 synthesis, sepiapterin, reverses MSPH–reduced vein dilation. 
4. Reduced BH4 synthesis leads to lower NO synthesis and bioavailability in HUVECs. 
5. MSPH–associated alterations may determine in uterus fetal vascular programming. 
